AnimaBiotech
We are a technology company with a platform for the discovery of small molecule mRNA drugs. Our technology platform combines novel biology, high scale automated screening and cloud-based computational biology of mRNA imaging analysis with AI software. We develop our own pipeline and partner with pharma on additional targets.
Pharma Collaborations
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
Up to $120 million in upfront and preclinical research milestone payments, up to $1.1 billion in clinical and commercial milestones and tiered royalties on sales of any Takeda products resulting from the collaboration. Takeda has a time limited option to expand the collaboration subject to additional payments to Anima of up to $1.2 billion and tiered royalties.
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.
For partnering inquiries, please contact [email protected].
A novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins.
Our technology platform combines novel biology, high scale automated screening and cloud-based computational biology for mRNA image analysis with AI software.
Translation Control Therapeutics platform
The signature tRNA pair selected by Cerebio for the protein of interest is labeled with fluorescent colors and transfected into cells. Translationlight then generates millions of images showing the translation of the mRNA of the protein in the presence of hundreds of thousands of tested molecules.
The images are uploaded to the cloud for analysis by Brightny where computational biology algorithms for mRNA imaging analysis with AI software identify compounds that decrease or increase the light emitted from the ribosomes. The active molecules are passed on to Compass, where computational and live biology are run in close loop iterations to systematically elucidate their mechanisms of action in the novel target space of mRNA translation modulators.
The Selectivity of Translation Biology
Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.
mRNA translation modulators
A novel target space
Biology
Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation
mRNA Translation Modulators Pipeline
The high scale automation and integrated technologies in our platform enabled us to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. With our tremendous expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.
Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors across several fibrotic diseases), Oncology (c-Myc and K-Ras translation inhibitors with multiple, tumor specific mechanisms of action), Infectious diseases (RSV viral proteins translation inhibitors) and Neuroscience (Tau - Alzheimer’s disease and pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.
| Indication | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|
Anima owned |
|||||
Fibrosis |
|||||
| Lung Fibrosis | 1 | ||||
| Collagen-1 | 2 | ||||
| 3 | |||||
| Liver Fibrosis | 4 | ||||
Oncology |
|||||
| c-Myc tumors | c-Myc | 5 | |||
| 6 | |||||
| 7 | |||||
| mKRAS tumors | mKRAS | 8 | |||
Infectious diseases |
|||||
| Respiratory | RSV | 9 | |||
| 10 | |||||
Neuroscience |
|||||
| Alzheimer | TAU | 11 | |||
| Repeat diseases | Undisclosed | 12 | |||
| Pain | Nav 1.7 | 13 | |||
Partnered |
|||||
| Huntington | mHTT | 14 | |||
| Undisclosed |
|
15 | |||
| Undisclosed | 16 | ||||
| Undisclosed | 17 | ||||
| Undisclosed | 18 | ||||
| Area | Indication | mRNA modulation | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|---|---|
| Fibrosis | Lung Fibrosis | 1 | |||||
| Collagen-1 | 2 | ||||||
| 3 | |||||||
| Liver Fibrosis | 4 | ||||||
| Oncology | c-Myc tumors | c-Myc | 5 | ||||
| 6 | |||||||
| 7 | |||||||
| mKRAS tumors | mKRAS | 8 | |||||
| Infectious diseases | Respiratory | RSV | 9 | ||||
| 10 | |||||||
| Neuroscience | Alzheimer | TAU | 11 | ||||
| Repeat diseases | Undisclosed | 12 | |||||
| Pain | Nav 1.7 | 13 | |||||
| Undisclosed |
|
14 | |||||
| Huntington | mHTT | 15 | |||||
| Undisclosed | 16 | ||||||
| Undisclosed | 17 | ||||||
| Undisclosed | 18 | ||||||
17 Scientific Collaborations
15 Peer Reviewed Publications
-
Measuring mRNA translation in neuronal processes and somata by tRNA-FRET
Nucleic Acids Res. 2020 ;46(6):e32 -
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62.
Coverage
News & Events
-
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.
-
Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs
When: May. 18th, 2021 - May. 19th, 2021
Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference.
-
Sachs 4th Annual Neuroscience Innovation Forum
When: Apr. 28th, 2021 - Apr. 30th, 2021
Anima Biotech has been invited to participate in a live panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum.